Khosla Ven­tures helps seed a next-gen re­gen­er­a­tive med­i­cines start­up boast­ing AI-based stem cell cul­tur­ing tech­nol­o­gy

A start­up in the bustling Boston-area biotech hub hopes its new tech­nol­o­gy has solved a time-con­sum­ing as­pect of de­vel­op­ing drugs that re­ly on cell ther­a­py: hav­ing to re­move stem cells by hand, in­di­vid­u­al­ly, dur­ing the man­u­fac­tur­ing process.

Celli­no, a re­gen­er­a­tive med­i­cine com­pa­ny, an­nounced Mon­day that it con­clud­ed a $16 mil­lion seed fi­nanc­ing round that will fur­ther ad­vance tech­nol­o­gy that us­es ar­ti­fi­cial in­tel­li­gence and a per­son­al­ized tis­sue and cell plat­form and ul­ti­mate­ly seeks to gen­er­ate au­tol­o­gous in­duced pluripo­tent stem cells at scale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER